These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33237942)

  • 1. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide.
    Turk S; Turk C; Akbar MW; Kucukkaraduman B; Isbilen M; Demirkol Canli S; Malkan UY; Okay M; Ucar G; Sayinalp N; Haznedaroglu IC; Gure AO
    PLoS One; 2020; 15(11):e0242497. PubMed ID: 33237942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.
    Tyagi A; Pramanik R; Bakhshi R; Singh A; Vishnubhatla S; Bakhshi S
    Int J Hematol; 2019 Aug; 110(2):205-212. PubMed ID: 31119613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
    Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
    Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
    Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
    J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.
    Ritter J; Creutzig U; Schellong G
    Haematol Blood Transfus; 1990; 33():185-92. PubMed ID: 2182410
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
    Elsayed GM; Nassar HR; Zaher A; Elnoshokaty EH; Moneer MM
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):43-9. PubMed ID: 24565682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intensification of chemotherapy of acute myeloid leukemia in children: report on the studies of the AML-BFM 78 and AML-BFM 83 protocols].
    Creutzig U; Ritter I; Schellong G
    Gematol Transfuziol; 1991 Jan; 36(1):16-21. PubMed ID: 2065939
    [No Abstract]   [Full Text] [Related]  

  • 10. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia.
    Ghasemi M; Okay M; Turk S; Naeemaee R; Guver E; Malkan UY; Aksu S; Sayinalp N; Haznedaroglu IC
    J Renin Angiotensin Aldosterone Syst; 2019; 20(2):1470320319851310. PubMed ID: 31117912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
    Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
    Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R; Visani G; Milligan D; Saba H; Tallman M; Rowe JM; Wiernik PH; Ramek J; Dugan K; Lum B; Villena J; Davis E; Paietta E; Litchman M; Covelli A; Sikic B; Greenberg P
    Adv Exp Med Biol; 1999; 457():47-56. PubMed ID: 10500779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.
    Lu F; Zhang J; Ji M; Li P; Du Y; Wang H; Zang S; Ma D; Sun X; Ji C
    Int J Oncol; 2014 Jul; 45(1):383-92. PubMed ID: 24756163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic prognostic factors in childhood acute myeloid leukemia].
    Reinhardt D; Von Neuhoff C; Sander A; Creutzig U
    Klin Padiatr; 2012 Oct; 224(6):372-6. PubMed ID: 22821298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.
    Kolesnikova MA; Sen'kova AV; Pospelova TI; Zenkova MA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1362. PubMed ID: 33675187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.